Positron Corporation

Positron Corporation is a molecular imaging medical device company that specializes in manufacturing and selling state-of-the-art PET imaging systems and clinical services to nuclear medicine healthcare providers throughout North America. Founded in 1983 and based in Niagara Falls, NY, the company focuses on cardiac Positron Emission Tomography (PET) imaging, recognized as the gold standard in diagnostic nuclear imaging and the most effective method for detecting coronary artery disease in nuclear cardiology. Positron's innovative PET technology, clinical services, and practice solutions enable healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes while providing superior cost-effective medicine. One of their key products is the Attrius®, a dedicated PET only system that offers the latest in cardiac PET technology and is the only choice when looking for a new dedicated PET system. It provides excellent sensitivity with minimal radiation exposure and can perform routine quantitative measurements, making it advantageous in facilitating the adoption of cardiac PET and the growth of the nuclear cardiology imaging market. The company has also announced development of a state-of-the-art PET-CT 4D molecular imaging device that will enable nuclear cardiologists to utilize the full capabilities available in molecular imaging and nuclear medicine, and expand into serving the needs of the vast oncology diagnostics marketplace. Recently, Positron received a $1.50M Post-IPO Equity investment at 13 November 2012. With its commitment to advancing PET imaging technology through production and R&D ventures, including one with Neusoft Medical Systems, Positron Corporation is positioned as a key player in the biotechnology, healthcare, and manufacturing industries in the United States.